#United States #Middletown #Datwyler #LTS Device Technologies #Stevanato Group

Innovative Collaboration for Advanced Drug Delivery

In a significant development for the healthcare industry, Datwyler, LTS Device Technologies, and Stevanato Group have joined forces to enhance self-delivery options for large-volume drugs. Announced on January 16, 2026, this collaboration aims to address the growing demand for patient-centric drug delivery systems, particularly for larger volumes used in therapies such as oncology and monoclonal antibodies.

The Need for Change

As the pharmaceutical landscape evolves, there is a notable shift from hospital-based administration to at-home self-administration of drugs. A recent study by the Mayo Clinic revealed that 73% of participants prefer to administer their therapies at home after a 24-week treatment period. This preference underscores the urgent need for effective self-delivery solutions that cater to patients’ desires for convenience and control.

Datwyler, known for its high-value elastomer components, is collaborating with LTS Device Technologies, a pioneer in wearable drug delivery systems, and Stevanato Group, a leading name in drug containment and delivery solutions. Together, they aim to offer a pre-validated large-volume platform capable of speeding up the market introduction of self-administered therapies.

Key Features of the Collaboration

The newly unveiled platform, set to be showcased at Pharmapack in Paris on January 21-22, 2026, promises to provide innovative solutions for the delivery of large volumes of biologics and sensitive therapeutics. Key features of the platform include:

• - NeoFlex™ Plungers: Developed by Datwyler, these plungers enhance the functionality and safety of large-volume injection systems, enabling controlled delivery and greater comfort.
• - EZ-fill® Cartridges: Offered by Stevanato Group, these pre-sterilized cartridges support doses of up to 20mL, making them ideal for complex therapies while maintaining patient compliance.
• - LTS Device Technologies' Sorrel™ Platform: This versatile system allows for the efficient delivery of medications, reinforcing the collaboration’s commitment to improving patient outcomes.

Overcoming Challenges

Transitioning to self-administration of large-volume therapies poses unique challenges such as pain, tissue tolerability, and absorption kinetics. Many existing systems limit subcutaneous injections to lower volumes (typically 2mL), which can be inadequate for high-dose treatments. This collaboration addresses these hurdles by offering new solutions that safely deliver higher doses in patient-friendly formats.

Riccardo Marcon, Senior Vice President of Sales & Marketing at Stevanato Group, emphasized the pressing need for innovative solutions within the industry, particularly for self-administered settings. The joint effort of these three companies aims to significantly lower the barriers for pharmaceutical manufacturers, allowing them to meet patient demands effectively.

A Promising Future

This strategic alliance stands as a groundbreaking advancement in the field of drug delivery. By combining their strengths, Datwyler, LTS Device Technologies, and Stevanato Group are set to provide solutions that not only enhance the patient experience but remain committed to safety and therapeutic efficacy.

For those interested in the latest developments in self-delivery solutions, a presentation titled "When Size Matters: The Evolution of Self-Delivery Solutions for Subcutaneous Administration" will be held during Pharmapack, offering insights into the collaboration and product features. Presenters will include experts from all three companies.

As the demand for efficient, patient-centered healthcare continues to rise, this collaboration is poised to play a pivotal role in shaping the future of large-volume drug delivery, ensuring that healthcare transitions towards more accessible and personalized solutions for patients worldwide.